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Caveolin-1 is a major component of caveolae and plays a regulatory role in several signalling pathways. Caveolin-1 was
recently identiﬁed as a metastasis-related gene in prostate cancer. The clinical effects of caveolin-1 expression in pancreatic
carcinoma, however, remain unknown. In this study, we have investigated the relationship between caveolin-1 expression and
the clinicopathologic variables and clinical outcome in 79 patients with pancreatic adenocarcinoma undergoing surgical
resection. Caveolin-1 expression was determined by immunohistochemistry, using a polyclonal anti-caveolin-1 antibody.
Patients were divided into two groups based on the extent of caveolin-1 expression: a negative expression group
(immunoreactivity in less than 50% of cells) and a positive expression group. Positive caveolin-1 immunostaining was detected
in 32 cases (40.5% of total), while non-neoplastic ductal epithelium showed little or no staining. Positive caveolin-1 expression
was correlated with tumour diameter (P=0.0079), histopathologic grade (P=0.0272) and poor prognosis (P=0.0008). Upon
multivariate analysis with Cox’s proportional hazards model, positive caveolin-1 expression was shown to be an independent
negative predictor for survival (P=0.0358). These results suggest that caveolin-1 overexpression is associated with tumour
progression, thereby indicating a poor prognosis for certain patients undergoing surgical resection for pancreatic carcinoma.
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Pancreatic carcinoma is one of the most common and lethal malig-
nancies (Niederhuber et al, 1995). Despite developments in surgical
and non-surgical therapies, signiﬁcant improvements in long-term
survival have not been realized. The majority of patients present an
advanced disease at the time of diagnosis, because of the tumour’s
characteristic rapid progression and late detectability. Accordingly,
the resectability rate for pancreatic carcinoma is low in most series.
Tumour resection is performed in only 9–36% of all patients.
Even in those patients fortunate enough to have a resectable lesion,
the 5-year survival rate following resection is 11–24% (Conlon et
al, 1996; Yamamoto et al, 1998; Sener et al, 1999). The reasons
behind the aggressiveness of pancreatic carcinoma are not clearly
understood. Therefore, the identiﬁcation of biological markers that
correlate with clinicopathologic variables or prognosis is important
in understanding the characteristics of this neoplasm and selecting
patients who would beneﬁt most from multimodality treatment.
The 21–24 kDa molecule, caveolin-1, is a major structural
component of caveolae, 50–100 nm vesicular invaginations of
the plasma membrane that mediate molecular transport and signal
transduction activities. Caveolin-1 plays a regulatory role in several
signalling pathways, including the Src family tyrosine kinase,
epidermal growth factor receptor, Neu/HER2 (c-erbB2), protein
kinase C, transforming growth factor (TGF)-b/SMAD, and Wnt/
beta-catenin/lef-1 pathways (Engelman et al, 1998a; Galbiati et al,
2000; Razani et al, 2001). In prostate cancer, caveolin-1 has been
found to be a metastasis-related gene with an independent prog-
nostic value for patients following radical prostatectomy (Yang et
al, 1999). Recent study has also found an association between
caveolin-1 expression and less favourable prognoses in oesophageal
squamous cell carcinoma (Kato et al, 2002). On the other hand,
caveolin-1 has been reported as a tumour suppressor gene (Engel-
man et al, 1998b) and its expression level is reduced in several
cancers (Lee et al, 1998; Racine et al, 1999; Bender et al, 2000;
Wiechen et al, 2001a,b). Thus, the role of caveolin-1 in tumour
remains controversial.
In the present study, we examined the expression and clinical
impact of caveolin-1 in a cohort of patients with pancreatic carci-
noma, using immunohistochemical analysis. We found that
caveolin-1 is overexpressed in pancreatic carcinoma and has a
signiﬁcant prognostic value for patients with this disease.
MATERIALS AND METHODS
Patients and specimens
We studied surgically-resected specimens from 79 patients with
pancreatic ductal adenocarcinomas and seven with chronic
pancreatitis treated at the Department of Surgical Oncology of
Hokkaido University Hospital, the Department of Surgery of
Teinekeijinkai Hospital, and the Department of Surgery of Hokkai-
do Gastroenterology Hospital from 1992 to 1999. Among the 79
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www.bjcancer.compatients with cancer, 60 underwent pancreatico-duodenectomy
(Whipple operation), 14 underwent distal pancreatecomy and ﬁve
underwent total pancreatectomy with curative intent. All patients
received extended radical lymphadenectomy. Pancreatic resection
was not performed in patients with distant site metastases. Any
cases of cystadenocarcinoma or mucin-producing carcinoma were
excluded from this study. Pancreatic carcinoma tissues were
obtained from 44 men and 35 women with a median age of 63
years (range, 31–83 years). The median duration of follow-up
was 57.6 months (range, 3.8–103.8 months), and 59 patients
(74.7%) died during the follow-up period.
All specimens were ﬁxed in 10% formalin and embedded in
parafﬁn wax. Representative blocks were selected (based primarily
on the greatest dimensions of the tumour), and serial 4 mm-thick
sections were examined by immunohistochemistry. Histological
classiﬁcation of tumours was based on the World Health Organi-
zation criteria. All tumours were staged according to the pTNM
pathological classiﬁcation of the UICC (International Union
Against Cancer) (Sobin and Wittekind, 1997). Thirty of 79
patients had positive resection margin for carcinoma, as evaluated
microscopically.
Immunohistochemistry
Immunohistochemical reactions were carried out using the strepta-
vidin–biotin–peroxidase method. Sections were deparafﬁnized in
xylene and rehydrated through a graded series of ethanol/water.
Endogenous peroxidase was blocked with 3% hydrogen peroxide
for 10 min. Sections were washed twice in phosphate-buffered
saline (PBS) and incubated with 10% normal goat serum (Histo-
ﬁne SAB-PO kit; Nichirei, Tokyo, Japan) for 30 min. Primary
antibody (anti-caveolin-1 rabbit polyclonal antibody directed
against caveolin-1 residues 2–21, Santa Cruz Biotechnology, Santa
Cruz, CA, USA) was applied in a 1:400 dilution in PBS, and
sections were incubated overnight at 48C. After three additional
washes, sections were incubated with polyvalent biotinylated goat
anti-rabbit antibody for 30 min at room temperature. Sections
were washed three times in PBS and incubated with streptavidin-
conjugated peroxidase for 30 min at room temperature. After three
additional washes, the reaction product was visualized after incu-
bating with 3,3'-diaminobenzidine tetrahydrochloride (Histoﬁne
SAB-PO kit; Nichirei, Tokyo, Japan) for approximately 15 min
and then washing with distilled water. Sections were counterstained
in haematoxylin for 1 min and mounted in Permount (Micro
Slides; Muto-Glass, Tokyo, Japan). The smooth muscle cell
segments or endothelium, both known to be abundant in caveo-
lin-1, were used as positive controls. For a negative control,
nonimmune puriﬁed rabbit serum was used for the primary anti-
body. The number of stained cells per 1000 was determined
under a microscope (Olympus Optical Co, Ltd, Tokyo, Japan) in
three visual ﬁelds, at a magniﬁcation of 6200. When the total
number of cancer cells observed under microscope was less than
1000, all cells were counted. When over 50% of all cancer cell cyto-
plasm was stained, the tumour was considered caveolin-1 positive.
This cut-off value (50%) was adopted from previous reports (Yang
et al, 1999; Kato et al, 2002). The present study was performed
retrospectively, but all specimens were evaluated by three investiga-
tors who were blind to the patients’ clinical information.
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Figure 1 Representative examples of caveolin-1 immunostaining. (A) Caveolin-1 immunoreactivity was observed in less than 5% of cancer cells, while
endothelial cells showed strong staining as an internal control. (B) Strong staining both in the cytoplasm and on the membrane of cancer cells. Over 50% of
tumour cells were reactive. (C) Non-neoplastic ductal epithelium adjacent to cancer cells showed no immunoreactivity (arrow). (D) In chronic pancreatitis,
normal ductal epithelium showed no immunoreactivity. (Original magniﬁcations: A, B, D, 6200; C, 6100)
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Caveolin-1 immunoreactivity was assessed for association with
clinicopathologic variables using the following statistical tests: the
Mann–Whitney test for depth of invasion, pTNM stage and histo-
pathologic grade; the chi-square test or Fisher’s exact test for the
remaining variables. The Kaplan–Meier method was used to
generate survival curves, and survival differences were analysed
with the log-rank test, based on the status of caveolin-1 expression.
Univariate and multivariate analyses were performed using Cox’s
proportional hazard regression model. Probability values less than
0.05 were considered statistically signiﬁcant. All analyses were
performed using statistical analysis software (StatView, version
5.0; SAS Institute, Inc. Cary, NC, USA).
RESULTS
Caveolin-1 expression of pancreatic carcinoma and chronic
pancreatitis specimens
Caveolin-1 was expressed both on the cell membrane and in the
cytoplasm of cancer cells, as evidenced by the presence of stained
granular immunoreaction products. Out of the 79 specimens of
pancreatic carcinoma, seventeen specimens were immunoreactive
for caveolin-1 in less than 5% of cells (Figure 1A); 20 specimens
were immunoreactive in 5–25% of cells; 10 specimens were immu-
noreactive in 25–50% of cells; and 32 specimens were
immunoreactive in over 50% of cells (Figure 1B). According to
our criteria, 32 out of 79 (40.5%) tumours were positive for caveo-
lin-1. Histologically non-neoplastic ductal epithelium adjacent to
cancer cells showed little or no immunoreactivity with caveolin-1
(Figure 1C). In all chronic pancreatitis specimens, normal ductal
epithelium showed little or no staining, while the smooth muscle
and endothelial cells consistently stained positively (Figure 1D).
Caveolin-1 expression and clinicopathologic variables
(Table 1)
Caveolin-1 expression showed a signiﬁcant correlation with
tumour diameter (P=0.0079) and histopathologic grade
(P=0.0272). No signiﬁcant association was noted between caveo-
lin-1 expression and other clinicopathologic variables.
Caveolin-1 expression and prognosis
Survival curves of patients, grouped according to level of caveolin-
1 staining, are shown in Figure 2. The caveolin-1 positive group
had a signiﬁcantly poorer prognosis than the caveolin-1 negative
group (3-year survival rate was 4.8% vs 33.8%, respectively) (log-
rank test: P=0.0008). Upon univariate analysis with Cox’s propor-
tional hazards model, lymph node metastasis (P=0.0007), tumour
diameter (P=0.0027), positive surgical margin (P=0.0014) and
caveolin-1 immunopositivity (P=0.0011) were all positively corre-
lated with poor prognosis. Multivariate analyses indicated that
caveolin-1 positivity was an independent unfavourable prognostic
factor (P=0.0358; risk ratio, 1.880; 95% CI, 1.043–3.390), as were
the presence of lymph node metastases (P=0.0009) and a positive
surgical margin (P=0.0045) (Table 2).
DISCUSSION
The present study shows that: (1) the level of caveolin-1 expression
is elevated in pancreatic adenocarcinoma relative to non-neoplastic
ductal epithelium, (2) caveolin-1 expression is related to tumour
diameter and histopathologic grade, and (3) positive caveolin-1
expression is an independent unfavourable prognostic factor
following surgical resection.
The expression of caveolin-1 is elevated in various cancer tissues,
including prostate cancer, oesophageal squamous cell carcinoma,
colon cancer and breast cancer (Yang et al, 1998, 1999; Fine et
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Table 1 Association between caveolin-1 expression and clinicopatho-
logical variables
Caveolin-1
Negative (%) Positive (%)
Variables No. of cases n=47 n=32 P value
Age (years) 0.8476
563 36 21 (58) 15 (42)
563 43 26 (60) 17 (40)
Gender 0.7042
Male 44 27 (61) 17 (39)
Female 35 20 (57) 15 (43)
pT 0.0557
2 4 3 (75) 1 (25)
3 50 33 (66) 17 (34)
4 25 11 (44) 14 (56)
pN 0.2425
0 23 16 (70) 7 (30)
1 56 31 (55) 25 (45)
Stage (pTNM) 0.0649
II 17 12 (71) 5 (29)
III 37 24 (65) 13 (35)
IVA 25 11 (44) 14 (56)
Histopathologic Grade 0.0272*
1 25 19 (76) 6 (24)
2 46 25 (54) 21 (45)
3 8 3 (37) 5 (63)
Lymphatic invasion 0.4340
Negative 13 9 (69) 4 (31)
Positive 66 38 (58) 28 (42)
Venous invasion 0.0644
Negative 32 23 (72) 9 (28)
Positive 47 24 (51) 23 (49)
Tumour diameter 0.0079*
43.0 cm 39 29 (74) 10 (26)
43.0 cm 40 18 (45) 22 (55)
Surgical margin 0.3828
Negative 49 31 (63) 18 (37)
Positive 30 16 (53) 14 (47)
*Signiﬁcant; pT, depth of invasion (pTNM); pN, lymph node metastasis (pTNM).
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Figure 2 Kaplan–Meier analysis of the overall survival of patients with
negative and positive tumour caveolin-1 expression (log-rank test,
P=0.0008).
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caveolin-1 expression and clinicopathological variables has been
shown in these cases. In prostate cancer, caveolin-1 expression
positively correlated with Gleason score, positive surgical margin
and lymph node metastasis (Yang et al, 1999). In oesophageal
squamous cell carcinoma, expression of caveolin-1 was positively
correlated with histopathologic stage, lymph node metastasis and
distant metastasis (Kato et al, 2002). In the present study, positive
caveolin-1 expression was detected in 32 out of 79 tumours
(40.5%) in pancreatic carcinoma, while non-neoplastic ductal
epithelium showed little or no immunoreactivity. Moreover, caveo-
lin-1 immunopositivity is positively correlated with tumour
diameter and histopathologic grade in this cancer as well. These
results suggest that caveolin-1 overexpression may contribute to
the aggressiveness of pancreatic carcinoma.
Except for the case of prostate cancer, however, the molecular
and cellular underpinnings of the relationship between caveolin-1
expression and cancer progression remain unclear. In prostate
cancer, caveolin-1 both protects against androgen withdrawal-
induced apoptosis in vitro and in vivo (Nasu et al, 1998) and blocks
c-myc-induced apoptosis in cancer cells (Timme et al, 2000).
Moreover, caveolin-1 mediates testosterone-stimulated survival/
clonal growth and promotes metastatic activity (Li et al, 2001),
while overexpression of caveolin-1 potentiates ligand-dependent
androgen receptor activation (Lu et al, 2001). It is well known that
prostate cancer is androgen-dependent. Androgen receptor has also
been detected in cancerous tissues of pancreatic carcinoma
(Corbishley et al, 1986), and it is thought that testosterone
increases growth of this tumour (Greenway, 1998). Thus, a similar
mechanism may be at work in prostate cancer and pancreatic carci-
noma.
Interestingly, it has recently been reported that a caveolin-1
mutation at codon 132 was found in human breast cancer speci-
mens and that the mutated caveolin-1 induced cellular
transformation, activated the mitogen-activated protein kinase
(MAPK)-signalling pathway, and promoted invasion ability in
NIH3T3 cells (Hayashi et al, 2001). Following up this result, we
searched for this caveolin-1 mutation in 11 pancreatic cancer cell
lines, but found no mutation in the predicted functional domains
(including the scaffolding and membrane-spanning domain) (data
not shown). In light of this ﬁnding, we suggest that overexpression
of wild-type caveolin-1 may be associated with cancer progression
in pancreatic carcinoma.
Contrary to the above-mentioned studies, it has been reported
that caveolin-1 levels were reduced in a variety of cancer cell lines
and cancer specimens (including human breast cancer, lung
cancer, colon cancer, ovarian cancer and sarcoma) (Lee et al,
1998; Racine et al, 1999; Bender et al, 2000; Wiechen et al,
2001a,b). Under some conditions, caveolin-1 has been shown to
suppress growth of speciﬁc cell lines in vitro and in vivo (Koleske
et al, 1995; Engelman et al, 1997; Suzuki et al, 1998), and some
have suggested that caveolin-1 functions as a tumour suppressor
gene (Engelman et al, 1998b). The reasons behind this seemingly
contradictory evidence remain unclear. Lee et al (2000) suggest
that the diverse effects of caveolin-1 may be mediated by different
regions of the caveolin-1 molecule, and may depend on the
expression levels of other coexpressed molecules. It has been
reported that the oncosuppressive effect of caveolin-1 is mediated
through the caveolin-1 scaffolding domain (residues 82–101)
(Okamoto et al, 1998). c-Src, however, induces phosphorylation
of caveolin-1 at residue tyrosine 14. Tyrosine 14-phosphorylated
caveolin-1 confers binding to growth factor receptor-binding
protein 7 (Grb7) and augments both anchorage-independent
growth and epidermal growth factor (EGF)-stimulated cell migra-
tion (Lee et al, 2000). In pancreatic carcinoma, Src kinase
overexpression and activation has been reported (Lutz et al,
1998). Thus, caveolin-1 might cooperate with other molecules,
such as c-Src and Grb7, to stimulate tumour growth in pancreatic
carcinoma.
This is the ﬁrst study demonstrating the prognostic signiﬁcance
of caveolin-1 expression in pancreatic carcinoma. The 3-year survi-
val rate following surgical resection of the caveolin-1 negative
group was 33.8%, while that in the caveolin-1 positive group was
only 4.8%. Furthermore, multivariate analysis demonstrated that
positive caveolin-1 expression is an independent negative prognos-
tic factor. These results can increase the accuracy of prognosis for
patients with pancreatic carcinoma, following surgical resection.
Caveolin-1 overexpression in resected specimens may be a useful
index of adjuvant therapy for the patients with a high risk of poor
prognosis.
M
o
l
e
c
u
l
a
r
a
n
d
C
e
l
l
u
l
a
r
P
a
t
h
o
l
o
g
y
Table 2 Prognostic factors in Cox’s proportional hazards model
Univariate Multivariate
Variables Risk ratio 95% CI P value Risk ratio 95% CI P value
Age (years)
4/463 1.328 0.796–2.214 0.2767
Gender
Male/Female 1.189 0.708–1.997 0.5128
pT
2/3–4 1.318 0.408–4.255 0.6443
pN
1/0 3.150 1.625–6.106 0.0007* 3.252 1.618–6.536 0.0009*
Histopathologic grade
2–3/1 1.584 0.899–2.789 0.1113
Lymphatic invasion
+/7 1.800 0.852–3.802 0.1235
Venous invasion
+/7 1.665 0.979–2.831 0.0599
Tumour diameter (cm)
4/43.0 2.247 1.325–3.812 0.0027* 1.397 0.790–2.472 0.2506
Surgical margin
+/7 2.394 1.401–4.091 0.0014* 2.260 1.287–3.970 0.0045*
Caveolin-1
+/7 2.415 1.422–4.099 0.0011* 1.880 1.043–3.390 0.0358*
*Signiﬁcant; CI, conﬁdence interval.
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ã 2002 Cancer Research UK British Journal of Cancer (2002) 87(10), 1140–1144In summary, overexpression of caveolin-1 in pancreatic carcino-
ma may contribute to tumour progression and be a negative
prognostic predictor following surgery. For patients with a tumour
overexpressing caveolin-1, closer follow-up should be performed to
ﬁnd recurrence, and adjuvant therapy may be beneﬁcial. However,
at present, the role of caveolin-1 in pancreatic carcinoma remains
unclear, and elucidation awaits further investigation.
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